Given these data, what conclusions were drawn at a recent CHEST 2016 conference panel? Medscape reports.

For my part, I was unable to identify a specific mild OSA subgroup that could benefit from treatment. Largely on the basis of the CATNAP trial, I believe that the persons most likely to benefit will be profoundly sleepy at baseline and will be selected using oxygen desaturation criteria to identify hypopneas.